Emerald Health Pharmaceuticals Granted FDA Orphan Drug Designation for Systemic Scleroderma. Emerald Health Pharmaceuticals Inc. (EHP), which is developing medications based on cannabinoid science, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead molecule, EHP-101, for the treatment of systemic scleroderma. Globe Newswire, 10/20/2017. (Also see Endocannabinoid System)
Association between objective signs and subjective symptoms of dry eye disease in patients with systemic sclerosis. A significant correlation was found between the Ocular Surface Disease Index (OSDI) as a subjective parameter and disease duration. PubMed, Rheumatol Int, 09/07/2017. (Also see Sjögren's Syndrome)
CCL2 in the Circulation Predicts Long-Term Progression of Interstitial Lung Disease (ILD) in Patients With Early Systemic Sclerosis (SSc). Higher CCL2 levels in the circulation were predictive of ILD progression and poorer survival in patients with early SSc, which support the notion that CCL2 has a role as a biomarker and potential therapeutic target. PubMed, Arthritis Rheumatol, 2017 Sep;69(9):1871-1878. (Also see Pulmonary Fibrosis)
Spectrum of esophageal dysmotility in systemic sclerosis on high–resolution esophageal manometry as defined by Chicago classification. The severity of gastroesophageal reflux disease related endoscopic findings correlated with the degree of esophageal dysmotility on high–resolution esophageal manometry. PubMed, Dis Esophagus, 2017 Dec 1;30(12):1-6. (Also see Dysmotility Syndrome)
Diagnosing and managing scleroderma–related pulmonary arterial hypertension. This article describes scleroderma–related PAH and its diagnosis and management. PubMed, JAAPA, 2017 Sep;30(9):11-18. (Also see Pulmonary Hypertension Diagnosis)
Systematic review and meta–analysis of the epidemiology of polyautoimmunity in Sjögren's syndrome (secondary Sjögren's syndrome (sSS)) focusing on autoimmune rheumatic diseases. Prevalence rates of sSS vary widely in different populations and the results of this meta–analysis highlight the need for better quality population studies. PubMed, Scand J Rheumatol, 2017 Sep 20:1-14. (Also see Sjögren's Syndrome)
Cancers associated with systemic sclerosis (SSc) involving anti-RNA polymerase III antibodies. Anti-RNA polymerase III antibodies are useful for SSc diagnosis in patients without anti-centromere or anti-Scl70 antibodies and their presence must lead physicians to screen for associated cancer, even in the absence of clinical signs. PubMed, Ann Dermatol Venereol, 09/13/2017. (Also see Antibodies and Cancer)
TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.
We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: